Skip to main content
SpringerLink
Log in

HLA Class I Antigen Abnormalities in Tumors

  • Chapter
General Principles of Tumor Immunotherapy

  • 1086 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Ostrand-Rosenberg S (2004) Animal models of tumor immunity, immunotherapy and cancer vaccines. Curr. Opin. Immunol. 16:143–150

    Article  PubMed  CAS  Google Scholar 

  2. Rosenberg SA, Yang JC, Retifo NP (2004) Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10:909–915

    Article  PubMed  CAS  Google Scholar 

  3. Braud V, Jones E Y, McMichel A (1997) The human major histocompatibility complex class Ib molecule HLA-E binds signal sequence-derived peptides with primary anchor residues at positions 2 and 9. Eur. J. Immunol. 27:1164–1169

    Article  PubMed  CAS  Google Scholar 

  4. Ulbrecht M, Modrow R, Srivastava R, Pedersen P, Weiss EH (1998) Interaction of HLA-E with peptides and the peptide transporter in vitro: implications for its function in antigen presentation. J. Immunol. 160:4375–4385

    PubMed  CAS  Google Scholar 

  5. Ishitani A, Geraghty DE (1992) Alternative splicing of HLA-G transcripts yields proteins with primary structures resembling both class I and class II antigens. Proc. Natl. Acad. Sci. USA 89:3947–3951

    Article  PubMed  CAS  Google Scholar 

  6. O’ Callaghan CA, Bell JI (1998) Structure and function of the human MHC class Ib molecules HLA-E, HLA-F and HLA-G. Immunol. Rev. 163:129–38

    Article  CAS  Google Scholar 

  7. Paul P, Cabestre FA, Ibrahim EC, Lefebvre S, Hhalil-Daher I, Vazeux G, Quiles RM, Bermond F, Dausset J, Carosella ED (2000) Identification of HLA-G7 as a new splice variant of the HLA-G mRNA and expression of soluble HLA-G5, -G6, and –G7 transcripts in human transfected cells. Hum. Immunol. 61:1138–1149

    Article  PubMed  CAS  Google Scholar 

  8. Kumanovics A, Takada T, Lindahl KF (2003) Genomic organization of the mammalian MHC. Annu. Rev. Immunol. 21:629

    Article  PubMed  CAS  Google Scholar 

  9. Bahram S, Spies T (1996) Nucleotide sequence of a human MHC class I MICB cDNA. Immunogenet. 43:230–233

    CAS  Google Scholar 

  10. Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL, Spies T (1999) Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285:727–729

    Article  PubMed  CAS  Google Scholar 

  11. Bahram S (2000) MIC genes: from genetics to biology. Adv. Immunol. 76:1–60

    PubMed  CAS  Google Scholar 

  12. Natali PG, Bigotti A, Nicotra MR, Viora M, Manfredi D, Ferrone S (1984) Distribution of human class I (HLA-A,B,C) histocompatibility antigens in normal and malignant tissues of nonlymphoid origin. Cancer Res. 44:4679–4687

    PubMed  CAS  Google Scholar 

  13. Rousseau P, Masternak K, Krawczyk M, Reith W, Dausset J, Carosella ED, Moreau P (2004) In vivo, RFX5 binds differently to the human leukocyte antigen-E, -F, and -G gene promoters and participates in HLA class I protein expression in a cell type-dependent manner. Immunol. 111:53–65

    Article  CAS  Google Scholar 

  14. Crisa L, McMaster MT, Ishii JK, Fischer SJ, Salomon DR. (1997) Identification of a thymic epithelial cell subset sharing expression of the class Ib HLA-G molecule with fetal trophoblasts. J. Exp. Med. 186:289–298

    Article  PubMed  CAS  Google Scholar 

  15. Loke YW, King A, Burrows T, Gardner L, Bowen M, Hiby S, Howlett S, Holmes N, Jacobs D (1997) Evaluation of trophoblast HLA-G antigen with a specific monoclonal antibody. Tissue Antigens 50:135–146

    Article  PubMed  CAS  Google Scholar 

  16. Le Discorde M, Moreau P, Sabatier P, Legeais JJ, Carosella ED (2003) Expression of HLA-G in human cornea, an immune-privileged tissue. Hum. Immunol. 64:1039–1044

    Article  PubMed  CAS  Google Scholar 

  17. Groh V, Rhinehart R, Secrist H, Bauer S, Grabstein KH, Spies T (1999) Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc. Natl. Acad. Sci. USA 96:6879–6884

    Article  PubMed  CAS  Google Scholar 

  18. Groh V, Bahram S, Bauer S, Herman A, Beauchamp M, Spies T (1996) Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. Proc. Natl. Acad. Sci. U S A. 93:12445–12450

    Article  PubMed  CAS  Google Scholar 

  19. Chiang EY, Stroynowski I (2004) A non-classical MHC class I molecule restricts CTL-mediated rejection of a syngeneic melanoma tumor. J. Immunol. 173:4394–4401

    PubMed  CAS  Google Scholar 

  20. Braud V, Allan DSJ, O’Callaghan CA, Soderstrom K, D’Andrea A, Ogg GS, Lazetic S, Young NT, Bell JI. Phillips JH et al. (1998) HLA-E binds to natural killer cell receptors CD94/NKG2A, B, and C. Nature 391:795–799

    Article  PubMed  CAS  Google Scholar 

  21. Lee N, Llano M, Carretero M, Ishitani A, Navarro F, Lopez-Botet M, Geraghty DE (1998) HLA-E is the major ligand for the natural killer inhibitory receptor CD94/NKG2A. Proc. Natl. Acad. Sci. USA 95:5199–5204

    Article  PubMed  CAS  Google Scholar 

  22. Khalil-Daher I, Riteau B, Menier C, Sedlik C, Paul P, Dausset J, Carosella ED, Rouas-Freiss N (1999) Role of HLA-G versus HLA-E on NK function: HLA-G is able to inhibit NK cytolysis by itself. J. Reprod. Immunol. 43:175–182

    Article  PubMed  CAS  Google Scholar 

  23. Hofmeister V, Weiss EH (2003) HLA-G modulates immune responses by diverse receptor interactions. Semin. Cancer Biol. 13:317–323

    Article  PubMed  CAS  Google Scholar 

  24. Groh V, Steinle A, Bauer S, Spies T (1998) Recognition of stress-induced MHC molecules by intestinal epithelial gamma-delta T cells. Science 279:1737–1740

    Article  PubMed  CAS  Google Scholar 

  25. Groh V, Rhinehart R, Randolph-Habecker J, Topp MS, Riddell SR, Spies T (2001) Costimulation of CD8 alph/abeta T cells by NKG2D via engagement by MIC induced on virus-infected cells. Nat. Immunol. 2:255–260

    Article  PubMed  CAS  Google Scholar 

  26. Cerwenka A, Lanier LL (2003) NKG2D ligands: unconventional MHC class I-like molecules exploited by viruses and cancer, Tissue Antigens 61:335–343

    Google Scholar 

  27. Raulet DH (2003) Roles of the NKG2D immunoreceptor and its ligands. Nat. Rev. Immunol. 3:781–790

    Article  PubMed  CAS  Google Scholar 

  28. Bahram S, Inoko H, Shiina T, Radosavljevic M (2005) MIC and other NKG2D ligands: from none to too many. Curr. Opin. Immunol.17:505–509

    PubMed  CAS  Google Scholar 

  29. Trombetta ES, Mellman I (2005) Cell biology of antigen processing in vitro and in vivo. Ann. Rev. Immunol. 23:975–1028

    Article  CAS  Google Scholar 

  30. Ackerman A L, Kyritsis C, Tampé R and Cresswell P (2003) Early phagosomes in dendritic cells form a cellular compartment sufficient for cross presentation of exogenous antigens. Proc. Natl. Acad. Si. USA 100:12889–12894

    Article  CAS  Google Scholar 

  31. Rivett AJ, Hearn AR (2004) Proteasome function in antigen presentation: immunoproteasome complexes, peptide production, and interactions with viral proteins. Curr. Protein Pept. Sci. 5:153–161

    Article  PubMed  CAS  Google Scholar 

  32. Saveanu L, Carroll O, Lindo V, Del Val M, Lopez D, Lepelletier Y, Greer F, Schomburg L, Fruci D, Niedermann G, van Endert PM (2002) Concerted peptide trimming by human ERAP1 and ERAP2 aminopeptidase complexes in the endoplasmic reticulum. Nat. Immunol. 6:689–697

    Article  CAS  Google Scholar 

  33. Serwold T, Gonzalez F, Kim J, Jacob R, Shastri N (2002) ERAAP customizes peptides for MHC class I molecules in the endoplasmic reticulum. Nature 419:480–483

    Article  PubMed  CAS  Google Scholar 

  34. Paulsson K, Wang P (2003) Chaperones and folding of MHC class I molecules in the endoplasmic reticulum. Biochim. Biophys. Acta. 1641:1–12

    Article  PubMed  CAS  Google Scholar 

  35. Garrido F, Ruiz-Cabello F, Cabrera T, Perez-Villar JJ, Lopez-Botet M, Duggan-Keen M, Stern PL (1997) Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol. Today 18:89–95

    Article  PubMed  CAS  Google Scholar 

  36. Garcia-Lora A, Martinez M, Algarra I, Gaforio JJ, Garrido F (2003) MHC class I-deficient metastatic tumor variants immunoselected by T lymphocytes originate from the coordinated downregulation of APM components. Int. J. Cancer 106:521–527

    Article  PubMed  CAS  Google Scholar 

  37. Murray PG, Constandinou CM, Crocker J, Young LS, Ambinder RF (1998) Analysis of major histocompatibility complex class I, TAP expression, and LMP2 epitope sequence in Epstein-Barr virus-positive Hodgkin’s disease. Blood 92:2477–83

    PubMed  CAS  Google Scholar 

  38. Wetzler M, Baer MR, Stewart SJ, Donohue K, Ford L, Stewart CC, Repasky EA, Ferrone S (2001) HLA class I antigen cell surface expression is preserved on acute myeloid leukemia blasts at diagnosis and at relapse. Leukemia 15:128–133

    Article  PubMed  CAS  Google Scholar 

  39. Demant C, Mulder A, Deneys V, Worsham MJ, Maes P, Claas FH, Ferrone S (2004) Down-regulation of HLA-A and HLA-Bw6, but not HLA-Bw4, allospecificities in leukemic cells: an escape mechanism from CTL and NK attack? Blood. 103:3122–30

    Google Scholar 

  40. Lehmann F, Marchand M, Hainaut P, Pouillart P, Sastre X, Ikeda H, Boon T, Coulie PG. (1995) Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection. Eur. J. Immunol. 25:340–347

    Article  PubMed  CAS  Google Scholar 

  41. Restifo NP, Marincola FM, Kawakami Y, Taubenberger J, Yannelli JR, Rosenberg SA. (1996) Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J Natl Cancer Inst. 88:100–108

    Article  PubMed  CAS  Google Scholar 

  42. Kloor M, Becker C, Benner A, Woerner SM, Gebert J, Ferrone S, von Knebel Doeberitz M (2005) Immunoselective pressure and human leukocyte antigen class I antigen machinery defects in microsatellite unstable colorectal cancers. Cancer Research 65:6418–6424

    Article  PubMed  CAS  Google Scholar 

  43. Algarra I, Garcia-Lora A. Cabrera T, Ruiz-Cabello F and Garrido F (2004) The selection of tumor variants with altered expression of classical and non-classical MHC class I molecules: implications for tumor immune escape. Cancer Immunol. Immunother. 53:904–910

    Article  PubMed  CAS  Google Scholar 

  44. Seliger B, Maeurer MJ, Ferrone S (2000) Antigen-processing machinery breakdown and tumor growth. Immunol. Today. 21:455–64

    Article  PubMed  CAS  Google Scholar 

  45. Chang CC, Campoli M, Pestifo NP, Wang X, Ferrone S (2005) Immune selection of hot-spot UPbeta2-microglobulin gene mutations, HLA-A2 allospecificity loss, and antigen-processing machinery component down-regulation in melanoma cells derived from recurrent metastases following immunotherapy. J. Immunol. 174:1462–1474

    PubMed  CAS  Google Scholar 

  46. Bicknell DC, Kaklamanis L, Hampson R, Bodmer WF, Karran P (1996) Selection for ss2-microglobulin mutation in mismatch repair defective colorectal carcinomas. Curr. Biol. 6:1695–1697

    Article  PubMed  CAS  Google Scholar 

  47. Cabrera CM, Jimenez P, Cabrera T, Esparza C, Ruiz-Cabello F, Garrido F (2003) Total loss of MHC class I in colorectal tumors can be explained by two molecular pathways: b2-microglobulin inactivation in MSI-positive tumors and LMP7/TAP2 downregulation in MSI-negative tumors. Tissue Antigens 61:211–219

    Article  PubMed  CAS  Google Scholar 

  48. Chen HL, Gabrilovich D, Tampe R, Girgis KR, Nadaf S, Carbone DP (1996) A functionally defective allele of TAP1 results in loss of MHC class I antigen presentation in a human lung cancer. Nat. Genet.13:210–213

    Article  PubMed  CAS  Google Scholar 

  49. Benitez R, Godelaine D, Lopez-Nevot MA et al. (1998) Mutations of the ss2-microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides. Tissue Antigens 52:520–529

    PubMed  CAS  Google Scholar 

  50. Hicklin DJ, Wang Z, Arienti F, Rivoltini L, Parmiani G, Ferrone S (1998) beta2-microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma. J. Clin. Invest. 101:break2720–2729

    Google Scholar 

  51. Feenstra M, rozemuller E, Duran K, Stuy I, van den Tweel J, Slootweg P, de Weger R, Tilanus M. (1999) Mutation in the beta 2m gene is not a frequent event in head and neck squamous cell carcinomas. Hum Immunol. 60:697–706

    Article  PubMed  CAS  Google Scholar 

  52. Atkins D, Ferrone S, Schmahl GE, Storkel S, Seliger B (2004) Down-regulation of HLA class I antigen processing molecules: an immune escape mechanism of renal cell carcinoma. J. Urol. 171:885–889

    Article  PubMed  CAS  Google Scholar 

  53. Raffaghello L, Prigione I, Bocca P, Morandi F, Camoriano M, Gambini C, Wang X, Ferrone S, Pistoia V (2005) Multiple defects of the antigen-processing machinery components in human neuroblastoma: immunotherapeutic implications. Oncogene 24:4634–4644

    Article  PubMed  CAS  Google Scholar 

  54. Romero JM, Jiménez P, Cabrera T, Cózar JM, Pedrinaci S, Tallada M, Garrido F, Ruiz-Cabello F (2005) Coordinated downregulation of the antigen presentation machinery and HLA class I/?2-microglobulin complex is responsible for HLA-ABC loss in bladder cancer. Int. J. Cancer 113:605–610

    Article  PubMed  CAS  Google Scholar 

  55. Cabrera CM, Jimenez P, Concha A, Garrido F, Ruiz-Cabello F (2004) Promyelocytic leukemia (PML) nuclear bodies are disorganized in colorectal tumors with total loss of major histocompatibility complex class I expression and LMP7 downregulation. Tissue Antigens 63:446–452

    Article  PubMed  CAS  Google Scholar 

  56. Seliger B, Ritz U, Abele R, Bock M, Tampe R, Sutter G, Drexler I, Huber C, Ferrone S (2001) Immune escape of melanoma: First evidence of structural alterations in two distinct components of the MHC class I antigen processing pathway. Cancer Res. 61:8647–8650

    PubMed  CAS  Google Scholar 

  57. Vitale M, Pelusi G, Taroni B, Gobbi G, Micheloni C, Rezzani R, Donato F, Wang X, Ferrone S (2005) HLA class I antigen down-regulation in primari ovary carcinoma lesions: association with disease stage. Clin. Cancer Res. 11:67–72

    PubMed  CAS  Google Scholar 

  58. Fowler NL, Frazer IH (2004) Mutations in TAP genes are common in cervical carcinomas. Gynecol. Oncol. 92:914–921

    Article  PubMed  CAS  Google Scholar 

  59. Yang T, McNally BA, Ferrone S, Liu Y, Zheng P (2003) A single-nucleotide deletion leads to rapid degradation of TAP-1 mRNA in a melanoma cell line. J. Biol. Chem. 278:15291–15296

    Article  PubMed  CAS  Google Scholar 

  60. Dutta N, Majumder D, Gupta A, Mazumber DN, Banerjee S (2005) Analysis of human lymphocyte antigen class I expression in gastric cancer by reverse transcriptase-polymerase chain reaction. Hum. Immunol. 66 :164–169

    Article  PubMed  CAS  Google Scholar 

  61. Sheu BC, Chiou SH, Chang WC, Chow SN, Lin HH, Chen RJ, Huang SC, Ho HN, Hsu SM (2005) Integration of high risk human papillomavirus DNA correlates with HLA genotype aberration and reduced HLA class I molecule expression in human cervical carcinoma. Clin. Immunol. 115:295–301

    Article  PubMed  CAS  Google Scholar 

  62. Ashrafi GH, Haghshenas MR, Marchetti B, O’Brien PM, Campo MS (2005) E5 protein of human papillomavirus type 16 selectively downregulates surface HLA class I. Int. J. Cancer 113:276–283

    Article  PubMed  CAS  Google Scholar 

  63. Seliger B, Dunn T, Schwenzer A, Casper J, Huber C, Schmoll HJ (1997) Analysis of the MHC class I kantigen presentation machinery in human embryonal carcinomas: evidence for deficiencies in TAP, LMP and MHC class I expression and their upregulation by IFN-gamma. Scand J Immunol. 46:625–32

    Article  PubMed  CAS  Google Scholar 

  64. Marrogi AJ, Munshi A, Merogi AJ, Ohadike Y, El-Habashi A, Marrogi OL, Freeman SM (1997) Study of tumor infiltrating lymphocytes and transforming growth factor-ss as prognostic factors in breast carcinoma. Int. J. Cancer 74:492–501

    Article  PubMed  CAS  Google Scholar 

  65. Naito Y, Saito K, Shiiba K, Ohuchi A, Saigenji K, Nagura H, Ohtani H (1998) CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res. 58:3491–3494

    PubMed  CAS  Google Scholar 

  66. Nakano O, Sato M, Naito Y, Suzuki K, Orikasa S, Aizawa M, Suzuki Y, Shintaku I, Nagura H, Ohtani H. (2001) Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer Res. 61:5132–5136

    PubMed  CAS  Google Scholar 

  67. Schumacher K, Haensch W, Roefzaad C, Schlag PM (2001) Prognostic significance of activated CD8+ T cell infiltrations within esophageal carcinomas. Cancer Res. 61:3932–3936

    PubMed  CAS  Google Scholar 

  68. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, Rubin SC, Coukos G (2003) Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348:203–213

    Article  PubMed  CAS  Google Scholar 

  69. Prall F, Dührkop T, Weirich V et al (2004) Prognostic role of CD8+ tumor-infiltrating lymphocytes in stage III colorectal cancer with and without microsatellite instability. Hum. Pathol. 35:808–816

    Article  PubMed  CAS  Google Scholar 

  70. Al-Batran SE, Rafiyan MR, Atmaca A, Neumann A, Karbach J, Bender A, Weidmann E, Altmannsberger HM, Knuth A and Jager E (2005) Intratumoral T-cell infiltrates and MHC class I expression in patients with stage IV melanoma. Cancer Res. 65:3937–3941

    Article  PubMed  CAS  Google Scholar 

  71. Sandel MH, Speetjens FM, Menon AG, Albertsson PA, Basse PH, Hokland M, Nagelkerke JF, Tollenaar RA EM, van de Velde CJH, Kuppen PJK (2005) Natural killer cells infiltrating colorectal cancer and MHC class I expression. Mol. Immunol. 42:541–546

    Article  PubMed  CAS  Google Scholar 

  72. Menon AG, Fleuren GJ, Alphenaar EA, Jonges LE., Janssen van Rhijn CM, Ensink NG, Putter H, Tollenaar RA, van de Velde CJ, Kuppen PJ (2002a) A basal membrane-like structure surrounding tumor nodules may prevent intraepithelial leukocyte infiltration in colorectal cancer. Cancer Immunol. Immunother. 52:121–126

    Google Scholar 

  73. Scrivener S, Goddard R, Kaminski E, Prentice A (2003) Abnormal T-cell function in B-cell chronic lymphocytic leukaemia. Leuk. Lymphoma 44:383–389

    Article  PubMed  CAS  Google Scholar 

  74. Gabrilovich DI, Chen HL, Girgis KR, Cunningham HT, Meny GM, Hadaf S, Kavanaugh D, Carbone DP (1996) Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med. 2:1096–1103

    Article  PubMed  CAS  Google Scholar 

  75. Medema JP, de Jong J, van Hall T, Melief CJ, Offringa R (1999) Immune escape of tumors in vivo by expression of cellular FLICE-inhibitory protein. J. Exp. Med. 190:1033–1038

    Article  PubMed  CAS  Google Scholar 

  76. Coleman S, Clayton A, Mason MD, Jasani B, Adams M, Tabi Z (2005) Recovery of CD8+ T-cell function during systemic chemotherapy in advanced ovarian cancer. Cancer Res. 65:7000–7006

    Article  PubMed  CAS  Google Scholar 

  77. Liotta LA, Kohn EC (2001) The microenvironment of the tumor-host interface. Nature 411:375–379

    Article  PubMed  Google Scholar 

  78. Gilboa E (2004) The promise of cancer vaccines. Nat. Rev. Cancer 4:401–411

    Article  PubMed  CAS  Google Scholar 

  79. Kammertoens T, Schüler T, Blankenstein T (2005) Immunotherapy: target the stroma to hit the tumor, Trends Mol Med.11:225–31

    Google Scholar 

  80. Spiotto MT, Schreiber H. (2005) Rapid destruction of the tumor microenvironment by CTLs recognizing cancer-specific antigens cross-presented by stromal cells. Cancer Immunity 5:8.

    PubMed  Google Scholar 

  81. Qin Z, Blankenstein T (2004) A cancer immunosurveillance controversy. Nat. Immunol. 5:3–4

    Article  PubMed  CAS  Google Scholar 

  82. Willimsky G., Blankenstein T (2005) Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature 437:141–6

    Article  PubMed  CAS  Google Scholar 

  83. Campoli M, Ferrone S, Zea AH, Rodriguez PC, Ochoa AC (2005) Mechanisms of tumor evasion. Cancer Treat. Res. 123:61–88

    Article  PubMed  CAS  Google Scholar 

  84. Cromme FV, Airey J, Heemels MT et al. (1994) Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas. J. Exp. Med. 179:335–340

    Article  PubMed  CAS  Google Scholar 

  85. Kaklamanis L, Townsend A, Doussis-Anagnostopoulou IA, Mortensen N, Harris AL, Gatter KC (1994) Loss of major histocompatibility complex-encoded transporter associated with antigen presentation (TAP) in colorectal cancer. Am. J. Pathol. 145:505–509

    PubMed  CAS  Google Scholar 

  86. Kaklamanis L, Leek R, Koukourakis M, Gatte KC, Harris AL (1995) Loss of transporter in antigen processing 1 transport protein and major histocompatibility complex class I molecules in metastatic versus primary breast cancer. Cancer Res. 55:5191–5194

    PubMed  CAS  Google Scholar 

  87. Vitale M, Rezzani R, Rodella L, Zauli G, Grigolato P, Cadei M, Hicklin DJ, Ferrone S (1998) HLA class I antigen and transporter associated with antigen processing (TAP1 and TAP2) down-regulation in high-grade primary breast carcinoma lesions. Cancer Res. 58:737–742

    PubMed  CAS  Google Scholar 

  88. Le YS, Kim TE, Kim BK et al (2002) Alterations of HLA class I and class II antigen expressions in borderline, invasive and metastatic ovarian cancers. Exp. Mol. Med. 34:18–26

    PubMed  Google Scholar 

  89. Krishnakumar S, Lakshmi SA, Abhyankar D, Biswa J (2004) Transporter associated protein expression in uveal melanoma. Br. J. Ophthalmol. 88:925–928

    Article  PubMed  CAS  Google Scholar 

  90. Meissner M, Reichert TE, Kunkel M, Gooding W, Whiteside TL, Ferrone S, Seliger B (2005) Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: association with clinical outcome. Clin. Cancer Res. 11:2552–2560

    Article  PubMed  CAS  Google Scholar 

  91. Kallfelz M, Jung D, Hilmes C, Knuth A, Jaeger E, Huber C, Seliger B (1999) Induction of immunogenicity of a human renal-cell carcinoma cell line by TAP1-gen transfer. Int. J. Cancer.81: 125–133

    Google Scholar 

  92. Qin Z, Harders C, Cao X, Huber C, Blankenstein T, Seliger B (2002) Increased tumorigenicity, but unchanged immunogenicity, of transporter for antigen presentation 1-deficient tumors. Cancer Res. 62:2856–2860

    PubMed  CAS  Google Scholar 

  93. Lou Y, Vitalis TZ, Basha G, Cai B, Chen SS, Choi KB, Jeffries AP, Elliott WM, Atkins D, Seliger B, Jefferies WA (2005) Restoration of the expression of transporters associated with antigen processing in lung carcinoma increases tumor-specific immune responses and survival. Cancer Res. 65:7926–7933

    PubMed  CAS  Google Scholar 

  94. Parmiani G, Castelli C, Dalerba P, Mortarini R, Rivoltini L, Marincola FM, Anichini A (2002) Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going. J. Natl. Cancer Inst. 94:805–818

    PubMed  CAS  Google Scholar 

  95. Agrawal S, Reemtsma K, Bagiella E, Oluwole SF and Braunstein NS (2004) Role of TAP-1 and/or TAP-2 antigen presentation defects in tumorigenicity of mouse melanoma. Cell. Immunol. 228:130–137

    Article  PubMed  CAS  Google Scholar 

  96. Jager MJ, Hurks HM, Levitskaya J, Kiessling R (2002) HLA expression in uveal melanoma: there is no rule without some exception. Hum. Immunol. 63:444–451

    Article  PubMed  CAS  Google Scholar 

  97. Menon AG, Morreau H, Tollenaar RA, Alphenaar E, Van Puijenbroek M, Putter H, Janssen-Van Rhijn CM, Van De Velde CJ, Fleuren GJ, Kuppen PJ (2002b) Down-regulation of HLA-A expression correlates with a better prognosis in colorectal cancer patients. Lab. Invest. 82:1725–1733

    CAS  Google Scholar 

  98. Madjd Z, Spendlove I, Pinder SE, Ellis IO, Durrant LG (2005) Total loss of MHC class I is an independent indicator of good prognosis in breast cancer. Int. J. Cancer 117:248–255

    Article  PubMed  CAS  Google Scholar 

  99. Ramnath N, Tan D, Li Q, Hylander BL, Bogner P, Ryes L, Ferrone S (2005) Is downregulation of MHC class I antigen expression in human non-small cell lung carcinoma associated with prolonged survival? Cancer Immunol. Immunother. 27:1–9

    Google Scholar 

  100. Cao B, Tian X, Li Y, Jiang P, Ning T, Xing H, Zhao Y, Zhang C, Shi X, Chen D, Shen Y, Ke Y (2005) LMP7/TAP2 gene polymorphisms and HPV infection in esophageal carcinoma patients from a high incidence area in China. Carcinogen. 26:1280–1284

    Article  CAS  Google Scholar 

  101. Seliger B, Bock M, Ritz U, Huber C (2002) High frequency of a non-functional TAP1/LMP2 promoter polymorphism in human tumors. Int. J. Oncol. 20:349–353 s

    PubMed  CAS  Google Scholar 

  102. McCluskey J, Rossjohn J, Purcell AW (2004) TAP genes and immunity. Curr. Opin. Immunol. 16:651–659

    Article  PubMed  CAS  Google Scholar 

  103. Ibrahim EC, Aractingi S, Allory Y, Borrini F, Dupuy A, Duvillard P, Carosella ED, Avril MF, Paul P (2004) Analysis of HLA antigen expression in benign and malignant melanocytic lesions reveals that upregulation of HLA-G expression correlates with malignant transformation, high inflammatory infiltration and HLA-A1 genotype. Int. J. Cancer 108:243–250

    Article  CAS  PubMed  Google Scholar 

  104. Real LM, Cabrera T, Collado A, Jimenez P, Garcia A, Ruiz-Cabello F, Garrido F (1999) Expression of HLA-G in human tumors is not a frequent event. Int. J. Cancer 81:512–518

    Article  PubMed  CAS  Google Scholar 

  105. Fukushima Y, Oshika Y, Nakamura M, Tokunaga T, Hatanaka H, Abe Y, Yamazaki H, Kijima H, Ueyama Y, Tamaoki N (1998) Increased expression of human histocompatibility leucocyte antigen-G in colorectal cancer cells. Int. J. Mol. Med. 2:349–351

    PubMed  CAS  Google Scholar 

  106. Paul P, Rouas-Freiss N, Khalil-Daher I, Moreau P, Riteau B, Le Gal FA, Avril MF, Dausset J, Guillet JG, Carosella ED (1998) HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance. Proc. Natl. Acad. Sci. USA 95:4510–4515

    Article  PubMed  CAS  Google Scholar 

  107. Paul P, Canestre FA, Le Gal FA, Khalil-Daher I, Le Danff C, Schmid M, Mercier S, Avril MF, Dausset J, Guillet JG, Carosella ED (1999) Heterogeneity of HLA-G gene transcription and protein expression in malignant melanoma biopsies. Cancer Res. 59:1954–1960

    PubMed  CAS  Google Scholar 

  108. Ibrahim EC, Morange M, Dausset J, Carosella ED, Paul P (2000) Heat shock and arsenite induce expression of the non-classical class I histocompatibility HLA-G gene in tumor cell lines. Cell Stress Chaperones 5:207–218

    Article  PubMed  CAS  Google Scholar 

  109. Ibrahim EC, Guerra N, Lacombe MJ, Angevin E, Chouaib S, Carosella ED, Caignard A, Paul P (2001) Tumor up-regulaton of the non-classical class I HLA-G antigen expression in renal carcinoma. Cancer Res. 61: 6838–6845

    Google Scholar 

  110. Urosevic M, Kurrer MO, Kamarashev J, Mueller B, Weder W, Burg G, Stahel RA, Dummer R, Trojan A (2001) Human leukocyte antigen G up-regulation in lung cancer associates with high-grade histology human leukocyte antigen class I loss and interleukin-10 production. Am. J. Pathol. 159:817–824

    PubMed  CAS  Google Scholar 

  111. Wiendl H, Mitsdoerffer M, Hofmeister V, Wischhusen J, Bornemann A, Meyermann R, Weis EH, Melms A, Weller M (2002) A functional role of HLA-G expression in human gliomas: an alternative strategy of immune escape. J. Immunol. 168:4772–4780

    PubMed  CAS  Google Scholar 

  112. Chang CC, Ferrone S (2003) HLA-G in melanoma: can the current controversies be solved? Semin. Cancer Biol. 13:361–369

    Article  CAS  Google Scholar 

  113. Davidson B, Elstrand MB, McMaster MT, Berner A, Kurman RJ., Risberg B, Trope CG. Shih IM (2005) HLA-G expression in effusions is a possible marker of tumor susceptibility to chemotherapy in ovarian carcinoma. Gynecol. Oncol. 96:42–47

    Article  PubMed  CAS  Google Scholar 

  114. Urosevic M, Willers J, Mueller B, Kempf W, Burg G, Dummer R (2002a) HLA-G protein up-regulation in primary cutaneous lymphomas is associated with interleukin-10 expression in large cell T-cell lymphomas and indolent B-cell lymphomas. Blood 99:609–617

    Article  CAS  Google Scholar 

  115. Urosevic M, Kempf W, Zagrodnik B, Panizzon R, Burg G, Dummer R (2005) HLA-G expression in basal cell carcinomas of the skin recurring after radiotherapy. Clin. Exp. Dermatol. 30:422–425

    Article  PubMed  CAS  Google Scholar 

  116. Marin R, Ruiz-Cabello F, Pedrinaci S, Mendez R, Jimenez P, Geraghty DE, Garrido F (2003) Analysis of HLA-E expression in human tumors. Immunogenet. 54:767–775

    CAS  Google Scholar 

  117. Palmisano GL, Contardi E, Morabito A, Gargaglione V, Ferrara GB, Pistillo MP (2005) HLA-E surface expression is independent of the availability of HLA class I signal sequence-derived peptides in human tumor cell lines. Hum. Immunol. 66:1–12

    Article  PubMed  CAS  Google Scholar 

  118. Mouillot G, Marcou C, Rousseau P, Rouas-Freiss N, Carosella ED, Moreau P (2005) HLA-G gene activation in tumor cells involves cis-acting epigenetic changes, Int. J. Cancer 113:928–936

    Article  CAS  Google Scholar 

  119. Rouas-Freiss N, Bruel S, Menier C, Marcou C, Moreau P, Carosella ED (2005) Switch of HLA-G alternative splicing in a melanoma cell line causes loss of HLA-G1 expression and sensitivity to NK lysis. Int. J. Cancer 117:114–122

    Article  PubMed  CAS  Google Scholar 

  120. Urosevic M, Trojan A, Dummer R (2002b) HLA-G and its KIR ligands in cancer-another enigma yet to be solved? J. Pathol. 196:252–253

    Article  Google Scholar 

  121. Wagner SN, Rebmann V, Willers CP, Grosse-Wilde H, Goos M (2000) Expression analysis of classic and non classical HLA molecules before interferon alfa-2b treatment of melanoma. Lancet 356:220–221

    Article  PubMed  CAS  Google Scholar 

  122. Ugurel S, Rebmann V, Ferrone S, Tilgen W, Grosse-Wilde H, Reinhold U (2001) Soluble human leukocyte antigen-G serum level is elevated in melanoma patient and is further increased by interferon-alpha immunotherapy. Cancer 92:369–376

    Article  PubMed  CAS  Google Scholar 

  123. Lefebvre S, Antioin, Uzan S, McMaster M, Dausset J, Carosella ED, Paul P (2002) Specific activation of the non-classical class I histocompatibility HLA-G antigen and expression of the ILT2 inhibitory receptor in human breast cancer. J. Pathol. 196:266–274

    Article  PubMed  CAS  Google Scholar 

  124. Rebmann V, Regel J, Stolke D, Grosse-Wilde H. (2003) Secretion of sHLA-G molecules in malignancies. Semin Cancer Biol. 13:371–7

    Article  PubMed  CAS  Google Scholar 

  125. Tomasec P, Braud VM, Rickards C, Powell MB, McSharry BP, Gadola S, Cerundolo V, Borysiewicz LK, McMichael AJ, Wilkinson GW (2000) Surface expression of HLA-E, an inhibitor of natural killer cells, enhanced by human cytomegalovirus gpUL40. Science 287:1031

    Google Scholar 

  126. Ljunggren HG, Karre K (1985) Host resistance directed selectively against H-2-deficient lymphoma variants: analysis of the mechanism. J. Exp. Med. 162:1745–1759

    Article  PubMed  CAS  Google Scholar 

  127. Vetter CS, Groh V, thor Straten P, Spies T, Brocker EB, Becker JC (2002) Expression of stress- induced MHC class I related chain molecules on human melanoma. J. Invest. Dermatol. 118:600–605

    Article  PubMed  CAS  Google Scholar 

  128. Jinushi M, Takehara T, Tatsumi T, Kanto T, Groh V, Spies T, Kimura R, Miyagi T, Mochizuki K, Sasaki Y, Hayashi N (2003) Expression and role of MICA and MICB in human hepatocellular carcinomas and their regulation by retinoic acid. Int. J. Cancer. 104:354–361

    Article  PubMed  CAS  Google Scholar 

  129. Salih HR, Rammensee HG, Steinle A (2002) Down-regulation of MICA on human tumors by proteolytic shedding. J. Immunol. 169:4098–4102

    PubMed  CAS  Google Scholar 

  130. Groh V, Wu J, Yee C, Spies T (2002) Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419:734–738

    Article  PubMed  CAS  Google Scholar 

  131. Vetter CS, Lieb W, Bröcker EB, Becker JC (2004) Loss of nonclassical MHC molecules MIC-A/B expression during progression of uveal melanoma. Brit. J. Cancer 91:1495–1499

    PubMed  CAS  Google Scholar 

  132. Wu JD, Higgin LM, Steinle A, Cosman D, Haugk K, Plymate SR (2004) Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer. J. Clin. Invest. 114:560–568

    Article  PubMed  CAS  Google Scholar 

  133. Watson NF, Spendlove I, Madjg Z, McGilvray R, Green AR, Ellis IO, Scholefield JH, Durrant LG (2005) Expression of the stress-related MHC class I chain-related protein MICA is an indicator of good prognosis in colorectal cancer patients. Int. J. Cancer 118:1445–52

    Article  CAS  Google Scholar 

  134. Cerwenka A, Baron JL, Lanier LL (2001) Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc. Natl. Acad. Sci. USA 98:11521–11526

    Article  PubMed  CAS  Google Scholar 

  135. Germain C, Larbouret C, Cesson V, Donda A, Held W, Mach JP, Pelegrin A, Robert B (2005) MHC class I-related chain A conjugated to antitumor antibodies can sensitize tumor cells to specific lysis by natural killer cells. Clin. Cancer Res. 11:7516–7522

    Article  PubMed  CAS  Google Scholar 

  136. Doubrovina ES, Doubrovin MM, Vider E, Sisson RB, O’Reilly RJ, Dupont B, Vyas YM (2003) Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma. J. Immunol. 171:6891–6899

    PubMed  CAS  Google Scholar 

  137. Wiemann K, Mittrucker HW, Feger U, Welte SA, Yokoyama WM, Spies T, Rammensee HG, Steinle A (2005) Systemic NKG2D down-regulation impairs NK and CD8 T cell responses in vivo. J. Immunol. 175:720–729

    PubMed  CAS  Google Scholar 

  138. Rivoltini L, Canese P, Huber V, Iero M, Pilla L, Valenti R, Fais S, Lozupone F, Casati C, Castelli C, Parmiani G (2005) Escape strategies and reasons for failure in the interaction between tumor cells and the immune system: how can we tilt the balance towards immune-mediated cancer control? Expert Opin. Biol. Ther. 5:463–476

    CAS  Google Scholar 

  139. Mumberg D, Monach PA, Wanderling S, Philip M, Toledano AY, Schreiber RD, Schreiber H (1999) CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma. Proc. Natl. Acad. Sci. USA 96:8633–8638

    Article  PubMed  CAS  Google Scholar 

  140. Qin Z, Schwartzkopff J, Pradera F, Kammertoens T, Seliger B, Pircher H, Blankenstein T (2003) A critical requirement of interferon gamma-mediated angiostasis for tumor rejection by CD8+ T cells. Cancer Res. 63:4095–4100

    PubMed  CAS  Google Scholar 

  141. Chen HL, Gabrilovich D, Virmani A, Ratnani I, Girgis KR, Nadaf-Rahrof S, Fernandez-Vina M, Carbone DP. (1996) Structural and functional analysis of beta2 microglobulin abnormalities in human lung and breast cancer. Int J Cancer. 67:756–63

    Article  PubMed  CAS  Google Scholar 

  142. Krishnakumar S, Sundaram A, Abhyankar D, Krishnamurthy V, Shanmugam MP, Gopal L, Sharma T, Biswas J (2004) Major histocompatibility antigens and antigen-processing molecules in retinoblastoma. Cancer 100:1059–1069

    Article  PubMed  CAS  Google Scholar 

  143. Lee N, Geraghty DE (2003) HLA-F surface expression on B cell and monocyte cell lines is partially independent from tapasin and completely independent from TAP. J. Immunol. 171:5264–5271

    PubMed  CAS  Google Scholar 

  144. York IA, Grant EP, Dahl AM, Rock KL (2005) A mutant cell with a novel defect in MHC class I quality control. J. Immunol. 174:6839–6846

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Medical Immunology, Martin Luther University, 06112 Halle, Germany and Department of Immunology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA

    Barbara Seliger & Soldano Ferrone

Authors
  1. Barbara Seliger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Soldano Ferrone
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. The Tumor Immunology Laboratory, Division of Surgical Oncology, Columbia University, New York, NY

    Howard L. Kaufman

  2. Department of Medicine, Memorial Sloan-Kettering Cancer Center, Weill Medical College of Cornell University, New York, NY

    Jedd D. Wolchok

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer

About this chapter

Cite this chapter

Seliger, B., Ferrone, S. (2007). HLA Class I Antigen Abnormalities in Tumors. In: Kaufman, H.L., Wolchok, J.D. (eds) General Principles of Tumor Immunotherapy. Springer, Dordrecht. https://doi.org/10.1007/978-1-4020-6087-8_6

Download citation

Publish with us

Policies and ethics

Search

Navigation